For subcutaneous versus intramuscular research dosing considerations, see our breakdown on subcutaneous and intramuscular peptide injection, which covers needle gauge and depth recommendations relevant to reconstituted peptide delivery
BPC-157 is one of the most extensively referenced cytoprotective peptides, with studies spanning gastrointestinal, musculoskeletal, cardiovascular, and central nervous system research contexts
Similarly, 10 ug or 10ng/kg of BPC 157 was also administered to a group of test subjects through an intraperitoneal injection
Consumption of these products has resulted in numerous hospitalizations, [2] and the drugs have been reported to cause hallucinations, increased heartbeat and blood pressure, aggressive behavior, anxiety, muscle spasms, nausea, and vomiting
When administered under stable conditions, this injection can be extremely responsive
Retatrutide, an experimental drug, is only available through an Eli Lilly clinical trial